Insmed Incorporated

392 articles with Insmed Incorporated

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 03, 2022

  6/3/2022

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 24 new employees.

• Insmed Names Drayton Wise Chief Commercial Officer

  5/23/2022

  Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022.

• Insmed To Present at the H.C. Wainwright Annual Global Life Sciences Conference

  5/17/2022

  Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the H.C. Wainwright Annual Global Life Sciences Conference.

• Insmed Presents New Data Across Three Pillars at American Thoracic Society 2022 International Conference

  5/17/2022

  Insmed Incorporated reported data from seven presentations across three of its pillars—ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder —at the American Thoracic Society 2022 International Conference.

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 06, 2022

  5/6/2022

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 10 new employees.

• Insmed Reports First Quarter 2022 Financial Results and Provides Business Update

  5/5/2022

  Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.  

• Insmed to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022

  4/21/2022

  Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2022 financial results on Thursday, May 5, 2022.

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 07, 2022

  4/7/2022

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 20 new employees.

• Insmed to Showcase New Data Across Three Pillars at the American Thoracic Society 2022 International Conference

  3/28/2022

  Insmed Incorporated today announced that seven posters across three of its pillars—ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP)—will be presented at the American Thoracic Society (ATS) 2022 International Conference, taking place May 13-18, 2022, in San Francisco.

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Mar 04, 2022

  3/4/2022

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 15 new employees.

• Insmed To Present at the Cowen 42nd Annual Health Care Conference

  3/3/2022

  Insmed Incorporated today announced that management will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022 at 9:10 a.m. ET.

• Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update

  2/17/2022

   Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on the Company's business and pipeline.

• Insmed To Present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference

  2/10/2022

   Insmed Incorporated today announced that management will present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 18, 2022 at 10:00 a.m. ET.

• Insmed Reported Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  2/4/2022

  Insmed Incorporated today announced the granting of inducement awards to 10 new employees.

• Insmed to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide a Business and Pipeline Update on Thursday, February 17, 2022

  1/27/2022

  Insmed Incorporated today announced that it will release its fourth quarter and full year 2021 financial results on Thursday, February 17, 2022.

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Dec 06, 2021

  12/6/2021

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to six new employees.

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Nov 05, 2021

  11/5/2021

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 15 new employees.

• Insmed To Participate in Three November Conferences

  11/3/2021

  Insmed Incorporated Inc. today announced that management will participate in the virtual investor conferences.

• Insmed Reports Third Quarter 2021 Financial Results and Provides Business Update

  10/28/2021

  Insmed Incorporated today reported financial results for the third quarter ended September 30, 2021 and provided a business update.  

• Insmed Ranks No. 1 on Science's 2021 Top Biopharma Employers List

  10/28/2021

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that it has ranked as the top company to work for in Science's 2021 Top Employers Survey.